Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2021
M108 is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. The aim of this phase I study is to establish safety and Tolerability of different Dosage regimen in patients With Advanced Unresectable Solid Tumors in China.
Epistemonikos ID: fe4a09f17413b9f630485ac0f07e24ea76846824
First added on: Oct 02, 2023